Study of the Symptomatic Improvement in Patients With Fibromyalgia by Means of a Food Supplement (FIBROFIN)

Pilot Study of a Cohort of Patients Affected by Fibromyalgia for Symptomatic Improvement by Means of a Food Supplement

Fibromyalgia is a syndrome (set of symptoms) of unknown etiology and characterized by diffuse musculoskeletal pain and chronic fatigue. In addition, other symptoms such as cognitive alterations, sleep rhythm disturbances, psychiatric syndromes such as anxiety, depression, etc. Other very characteristic symptoms are hyperalgesia (very low pain threshold) and allodynia (amplified response to painful stimuli).

The treatment of fibromyalgia is symptomatic and the drugs only serve to reduce symptoms in some patients, in addition to the fact that these available treatments (antidepressants, pain signal modulators, rescue analgesics, etc.) have many side effects.

The food supplement which is the object of this study, FibrofixPlus®, is made up of a combination of natural substances.

This is the reason why this observational study aims to improve symptoms caused by fibromyalgia in patients treated with FibrofixPlus®.

Study Overview

• Status: Completed
• Conditions: Fibromyalgia
• Intervention / Treatment: Dietary supplement: Food supplement

Detailed Description

Patients who meet the fibromyalgia criteria according to the definition of the American College of Rheumatology (ACR) in 1990 and 2010, with a minimum score of 4 on the Visual Analogue Scale (VAS) of Fatigue and Pain and without any treatment (anxiolytics, neuroleptics, antidepressants and/or narcotic analgesics) in a minimum of 4 weeks prior to the beginning of the study, with some exceptions, and who do not meet any of the exclusion criteria will be invited to participate in the study.

There are three study visits which are distributed throughout 8 weeks.

• Study Type: Observational
• Enrollment (Actual): 30

Contacts and Locations

Study Locations

• Spain
  • Barcelona, Spain, 08036
    • Hospital Clinic Barcelona

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: Female

• Sampling Method: Probability Sample

Study Population

Women with fibromyalgia in primary care clinic.

Description

Inclusion Criteria:

• Women ≥ 18 years.
• Meet the fibromyalgia criteria according to the definition of the American College of Rheumatology of 1990 and 2010.
• Minimum score of 4 on the Visual Analogue Scale (VAS) for Fatigue and Pain.
• Period prior to the start of the study of a minimum of 4 weeks without treatment with anxiolytics, neuroleptics, antidepressants and/or narcotic analgesics. The use of paracetamol up to 2 g/day is allowed, and tramadol 100 mg/8h maximum.

Exclusion Criteria:

• Current diagnosis of a psychiatric disorder other than major depressive disorder.
• Pain caused by a traumatic or structural injury.
• Chronic inflammatory diseases.
• Autoimmune disease.
• Use of medications that may interfere with the assessment of pain improvement, including analgesics (with the exception stated in the inclusion criteria), antidepressants, anticonvulsants, or other medication taken to combat fibromyalgia, fatigue or pain.
• Rehabilitation with therapeutic intent.
• Intent to apply or current disability application process.
• Natural therapies (homeotherapy, acupuncture, food, etc.) to improve fibromyalgia.
• Hypersensitivity to the active principles or to any of the excipients of the products included in the study.
• Pregnancy.
• Breastfeeding.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Fibromyalgia patients; All patients will be administered with one sachet of food supplement (FibrofixPlus®) per day, for 8 weeks.	Dietary supplement: Food supplement; FibrofixPlus® is an authorized food supplement.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Symptomatic change of fibromyalgia through the Fibromyalgia Impact Questionnaire (s-FIQ), after taking the FibrofixPlus® food supplement, for 8 weeks.	To assess the magnitude of the symptomatic improvement by measuring the results to questions of the Fibromyalgia Impact Questionnaire (s-FIQ). This questionnaire scores from 0 to 100, being 0 the best quality of life and functional capacity, and 100 is the worst result.	From Visit 0, and at each visit (Visit 1 or 4 weeks after Visit 0; and Visit 2 or 8 weeks after Visit 0).

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of safety episodes.	All episodes will be recorded, whether considered minor or serious, food supplement-related or not.	Visit 1 to Visit 2, up to 4 weeks.
Change of fatigue symptom through the Visual Analogue Scale (VAS).	To assess the fatigue symptom by the completion of the Visual Analogue Scale (VAS). The VAS scores from 0 to 10, being 0 the best outcome (without fatigue) and 10 the worst outcome (maximum fatigue).	From Visit 0, and at each visit (Visit 1 or 4 weeks after Visit 0; and Visit 2 or 8 weeks after Visit 0).
Change of fatigue symptom through the Symptom Severity Score (SS Score).	To assess the fatigue symptom by the completion of the Symptom Severity Score (SS Score). The SS Score has a scoring from 0 to 12, being 0 the best outcome (without fatigue) and 12 the worst outcome (maximum fatigue).	From Visit 0, and at each visit (Visit 1 or 4 weeks after Visit 0; and Visit 2 or 8 weeks after Visit 0).
Change of pain symptom through the Visual Analogue Scale (VAS).	To assess the pain symptom by the completion of the Visual Analogue Scale (VAS). The VAS scores from 0 to 10, being 0 the best outcome (without fatigue) and 10 the worst outcome (maximum fatigue).	From Visit 0, and at each visit (Visit 1 or 4 weeks after Visit 0; and Visit 2 or 8 weeks after Visit 0).
Change of pain symptom through the Widespread Pain Index (WPI).	To assess the pain symptom by the completion of the Widespread Pain Index (WPI). The WPI scores from 0 to 19, being the highest result the worst outcome as defined by the number of body areas with pain.	From Visit 0, and at each visit (Visit 1 or 4 weeks after Visit 0; and Visit 2 or 8 weeks after Visit 0).
Change of pain symptom through the Symptom Severity Score (SS Score).	To assess the pain symptom by the completion of the Symptom Severity Score (SS Score). The SS Score has a scoring from 0 to 12, being 0 the best outcome and 12 the worst outcome.	From Visit 0, and at each visit (Visit 1 or 4 weeks after Visit 0; and Visit 2 or 8 weeks after Visit 0).
Change of the sleep quality through the Pittsburgh Sleep Quality Index (PSQI).	To assess the sleep quality by the completion of the Pittsburgh Sleep Quality Index (PSQI). The PSQI has a scoring from 0 to 21, being 0 the best outcome with no difficulties to sleep.	From Visit 0, and at each visit (Visit 1 or 4 weeks after Visit 0; and Visit 2 or 8 weeks after Visit 0).
Change of the sleep quality through the Symptom Severity Score (SS Score).	To assess the sleep quality by the completion of the Symptom Severity Score (SS Score). The SS Score has a scoring from 0 to 12, being 0 the best outcome and 12 the worst outcome.	From Visit 0, and at each visit (Visit 1 or 4 weeks after Visit 0; and Visit 2 or 8 weeks after Visit 0).
Change on the functional impairment through the questionnaire Clinical Global Impressions (CGI).	To assess the functional impairment by the completion of the Clinical Global Impressions (CGI). The CGI has a scoring from 0 to 7, being 0 "not assessed" and 1 "normal or not ill" and 7 "extremely ill".	From Visit 0, and at each visit (Visit 1 or 4 weeks after Visit 0; and Visit 2 or 8 weeks after Visit 0).
Change on the quality of life through the questionnaire Clinical Global Impressions (CGI).	To assess the quality of life by the completion of the questionnaire CGI. The CGI has a scoring from 0 to 7, being 0 "not assessed" and 1 "normal or not ill" and 7 "extremely ill".	From Visit 0, and at each visit (Visit 1 or 4 weeks after Visit 0; and Visit 2 or 8 weeks after Visit 0).
Change on the quality of life through the questionnaire Hospital Anxiety and Depression Scale (HADS).	To assess the quality of life by the completion of the HADS. The HADS has a maximum score of 21, which indicates a severe or worse status.	At Visit 0 and at Visit 2, or 8 weeks after Visit 0.
Change on the functional impairment through the questionnaire Short Form-36 Questionnaire (SF-36).	To assess the functional impairment by the completion of the Short Form-36 Questionnaire (SF-36). The SF-36 has several questions so when the scoring is higher, better is the health status. The global score is between 0 and 100, being 0 the worst and 100 the best health status.	At Visit 0 and at Visit 2, or 8 weeks after Visit 0.
Change on the quality of life through the questionnaire Short Form-36.	To assess the quality of life by the completion of the Short Form-36 Questionnaire (SF-36). The SF-36 has several questions so when the scoring is higher, better is the health status. The global score is between 0 and 100, being 0 the worst and 100 the best health status.	At Visit 0 and at Visit 2, or 8 weeks after Visit 0.

Collaborators and Investigators

• Sponsor: Arafarma Group, S.A.
• Investigators: Principal Investigator: Rodríguez Araya, Dr, Hospital Clinic of Barcelona

Study record dates

Study Major Dates

• Study Start (ACTUAL): March 9, 2022
• Primary Completion (ACTUAL): September 6, 2022
• Study Completion (ACTUAL): November 8, 2022

Study Registration Dates

• First Submitted: November 28, 2022
• First Submitted That Met QC Criteria: January 30, 2023
• First Posted (ACTUAL): February 8, 2023

Study Record Updates

• Last Update Posted (ACTUAL): February 10, 2023
• Last Update Submitted That Met QC Criteria: February 8, 2023
• Last Verified: February 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nervous System Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Muscular Diseases; Neuromuscular Diseases; Fibromyalgia; Myofascial Pain Syndromes
• Other Study ID Numbers: ARA-OBS/FIB-2021-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No